Resistant hypertension in the high-risk metabolic patient

Current Diabetes Reports

Volumn 11, Issue 1, 2011, Pages 41-46

  Chaudhary, Kunal ^a   Buddineni, J P ^b   Nistala, Ravi ^b   Whaley Connell, Adam ^b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adiponectin; Metabolic syndrome; Resistant hypertension

Indexed keywords

ADIPOCYTOKINE; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PRAVASTATIN; ROSIGLITAZONE;

ADRENERGIC SYSTEM; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WEIGHT REDUCTION;

ADIPONECTIN; HUMANS; HYPERTENSION; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY;

EID: 79551512794     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0155-x     Document Type: Article

References (63)

1. CM Alexander PB Landsman SM Teutsch SM Haffner 2003 NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 1210 1214 1:CAS:528:DC%2BD3sXjsFGhur0%3D 10.2337/diabetes.52.5.1210 12716754 (Pubitemid 36523358)
2. RH Eckel SM Grundy PZ Zimmet 2005 The metabolic syndrome Lancet 365 1415 1428 1:CAS:528:DC%2BD2MXjsVegtbg%3D 10.1016/S0140-6736(05)66378-7 15836891 (Pubitemid 40523737)
3. B Isomaa P Almgren T Tuomi, et al. 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 683 689 1:STN:280:DC%2BD3MvjsVOqsw%3D%3D 10.2337/diacare.24.4.683 11315831
4. HM Lakka DE Laaksonen TA Lakka, et al. 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709 2716 10.1001/jama.288.21.2709 12460094 (Pubitemid 35403784)
5. JL Probstfield KD O'Brien 2010 Progression of cardiovascular damage: the role of renin-angiotensin system blockade Am J Cardiol 105 1 Suppl 10A 20A 1:CAS:528:DC%2BD1MXhsFyitL%2FE 10.1016/j.amjcard.2009.10.006 20102969
6. AS Bomback R Toto 2009 Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination Am J Hypertens 22 1032 1040 1:CAS:528:DC%2BD1MXhtFGqt7fE 10.1038/ajh.2009.138 19661925
7. EP Kirk S Klein 2009 Pathogenesis and pathophysiology of the cardiometabolic syndrome J Clin Hypertens (Greenwich) 11 761 765 1:CAS:528:DC%2BC3cXkvF2htg%3D%3D 10.1111/j.1559-4572.2009.00054.x
8. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
9. JE Hall AA da Silva 2010 do Carmo JM, et al.: Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins J Biol Chem 285 17271 17276 1:CAS:528:DC%2BC3cXmslSntLc%3D 10.1074/jbc.R110.113175 20348094
10. Sowers JR: Endocrine functions of adipose tissue: focus on adiponectin. Clin Cornerstone 2008, 9:32-38; discussion 39-40.
11. K Rahmouni ML Correia WG Haynes AL Mark 2005 Obesity-associated hypertension: new insights into mechanisms Hypertension 45 9 14 1:CAS:528:DC%2BD2cXhtFaiu7rN 10.1161/01.HYP.0000154312.87612.07 15583075
12. HP Dustan 1983 Mechanisms of hypertension associated with obesity Ann Intern Med 98 5 Pt 2 860 864 1:STN:280:DyaL3s3gt1Cnsg%3D%3D 6342497
13. R Stamler J Stamler WF Riedlinger, et al. 1978 Weight and blood pressure. Findings in hypertension screening of 1 million Americans JAMA 240 1607 1610 1:STN:280:DyaE1M%2FgslKqsA%3D%3D 10.1001/jama.240.15.1607 691146 (Pubitemid 9047223)
14. Y Qi N Takahashi SM Hileman, et al. 2004 Adiponectin acts in the brain to decrease body weight Nat Med 10 524 529 1:CAS:528:DC%2BD2cXjsF2jtLw%3D 10.1038/nm1029 15077108 (Pubitemid 38667912)
15. M Vaz G Jennings A Turner, et al. 1997 Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects Circulation 96 3423 3429 1:STN:280:DyaK1c%2FlslWhsQ%3D%3D 9396437
16. F Massiera M Bloch-Faure D Ceiler, et al. 2001 Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation FASEB J 15 2727 2729 1:CAS:528:DC%2BD3MXptFags7k%3D 11606482
17. AM Sironi A Gastaldelli A Mari, et al. 2004 Visceral fat in hypertension: influence on insulin resistance and beta-cell function Hypertension 44 127 133 1:CAS:528:DC%2BD2cXlvVKlsb8%3D 10.1161/01.HYP.0000137982.10191.0a 15262911 (Pubitemid 39014227)
18. H Katagiri T Yamada Y Oka 2007 Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals Circ Res 101 27 39 1:CAS:528:DC%2BD2sXntVCitb0%3D 10.1161/CIRCRESAHA.107.151621 17615379 (Pubitemid 47094621)
19. H Tilg AR Moschen 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity Nat Rev Immunol 6 772 783 1:CAS:528:DC%2BD28XhtVSgurnN 10.1038/nri1937 16998510 (Pubitemid 44453463)
20. PA Sarafidis GL Bakris 2007 Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 21 12 19 1:CAS:528:DC%2BD28XhtlSqtb3E 10.1038/sj.jhh.1002103 17051236 (Pubitemid 44921815)
21. DA Morgan DR Thedens R Weiss K Rahmouni 2008 Mechanisms mediating renal sympathetic activation to leptin in obesity Am J Physiol Regul Integr Comp Physiol 295 R1730 R1736 1:CAS:528:DC%2BD1cXhsFSntbjF 18815209
22. T Kadowaki T Yamauchi N Kubota, et al. 2006 Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome J Clin Invest 116 1784 1792 1:CAS:528:DC%2BD28XmvV2ltL0%3D 10.1172/JCI29126 16823476 (Pubitemid 44033298)
23. RS Lindsay T Funahashi RL Hanson, et al. 2002 Adiponectin and development of type 2 diabetes in the Pima Indian population Lancet 360 57 58 1:CAS:528:DC%2BD38XltV2qs7Y%3D 10.1016/S0140-6736(02)09335-2 12114044 (Pubitemid 34756495)
24. M Daimon T Oizumi T Saitoh, et al. 2003 Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study Diabetes Care 26 2015 2020 1:CAS:528:DC%2BD3sXlvFCjtbg%3D 10.2337/diacare.26.7.2015 12832305 (Pubitemid 41184244)
25. J Krakoff T Funahashi CD Stehouwer, et al. 2003 Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian Diabetes Care 26 1745 1751 1:CAS:528:DC%2BD3sXkslKrtLs%3D 10.2337/diacare.26.6.1745 12766104 (Pubitemid 36929114)
26. J Spranger A Kroke M Mohlig, et al. 2003 Adiponectin and protection against type 2 diabetes mellitus Lancet 361 226 228 1:CAS:528: DC%2BD3sXkvVOlsQ%3D%3D 10.1016/S0140-6736(03)12255-6 12547549 (Pubitemid 36126226)
27. BB Duncan MI Schmidt JS Pankow, et al. 2004 Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study Diabetes 53 2473 2478 1:CAS:528:DC%2BD2cXns1Shsb8%3D 10.2337/diabetes.53.9.2473 15331562 (Pubitemid 39145606)
28. •• Greenstein AS, Khavandi K, Withers SB, et al.: Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009, 119:1661-1670. This is a study looking at the role of PVAT in maintaining vascular tone and its effect in obesity-associated hypertension.
29. R Cooper N McFarlane-Anderson FI Bennett, et al. 1997 ACE, angiotensinogen and obesity: a potential pathway leading to hypertension J Hum Hypertens 11 107 111 1:CAS:528:DyaK2sXjsFSju7Y%3D 10.1038/sj.jhh.1000391 9140797
30. M Caprio B Feve A Claes, et al. 2007 Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis FASEB J 21 2185 2194 1:CAS:528:DC%2BD2sXnvVagtr8%3D 10.1096/fj.06-7970com 17384139 (Pubitemid 47026453)
31. CM Rondinone D Rodbard ME Baker 1993 Aldosterone stimulated differentiation of mouse 3 T3-L1 cells into adipocytes Endocrinology 132 2421 2426 1:CAS:528:DyaK3sXkvVKmurw%3D 10.1210/en.132.6.2421 8504747 (Pubitemid 23156890)
32. JR Sowers A Whaley-Connell M Epstein 2009 Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 776 783 19487712
33. NJ Brown 2008 Aldosterone and vascular inflammation Hypertension 51 161 167 1:CAS:528:DC%2BD1cXmt1OhsQ%3D%3D 10.1161/HYPERTENSIONAHA.107.095489 18172061 (Pubitemid 351159920)
34. Y Miyata S Muto E Kusano 2005 Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H∈+∈exchange in vascular smooth muscle cells J Hypertens 23 2237 2250 1:CAS:528:DC%2BD2MXhtFOhsLfM 10.1097/01.hjh. 0000194122.27475.6c 16269966
35. S Ebata S Muto K Okada, et al. 1999 Aldosterone activates Na+/H∈+∈exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms Kidney Int 56 1400 1412 1:CAS:528:DyaK1MXmslGntbg%3D 10.1046/j.1523-1755.1999.00674.x 10504492 (Pubitemid 29451247)
36. S Kidambi JM Kotchen CE Grim, et al. 2007 Association of adrenal steroids with hypertension and the metabolic syndrome in blacks Hypertension 49 704 711 1:CAS:528:DC%2BD2sXhslCmsbo%3D 10.1161/01.HYP.0000253258.36141.c7 17159085
37. JH Miller MD Bogdonoff 1954 Antidiuresis associated with administration of insulin J Appl Physiol 6 509 512 1:CAS:528:DyaG2cXltVCltA%3D%3D 13129183
38. LA Sechi E Bartoli 1996 Molecular mechanisms of insulin resistance in arterial hypertension Blood Press Suppl 1 47 54 1:STN:280:DyaK2s%2Fhtlamsw%3D%3D 9162438
39. TJ Guzik PJ Marvar M Czesnikiewicz-Guzik R Korbut 2007 Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction J Physiol Pharmacol 58 591 610 1:CAS:528: DC%2BD1cXhtFKkt74%3D 18195475
40. P Shi MK Raizada C Sumners 2010 Brain cytokines as neuromodulators in cardiovascular control Clin Exp Pharmacol Physiol 37 e52 e57 1:CAS:528:DC%2BC3cXitFClt7c%3D 10.1111/j.1440-1681.2009.05234.x 19566837
41. G Grassi 2001 Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions J Hypertens 19 1713 1716 1:CAS:528:DC%2BD3MXnsFOnsb4%3D 10.1097/00004872-200110000-00003 11593089 (Pubitemid 32924935)
42. S Dimmeler I Fleming B Fisslthaler, et al. 1999 Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation Nature 399 601 605 1:CAS:528:DyaK1MXjvFegu7s%3D 10.1038/21224 10376603 (Pubitemid 29279182)
43. C Vecchione A Maffei S Colella, et al. 2002 Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway Diabetes 51 168 173 1:CAS:528:DC%2BD38Xlt1ehsQ%3D%3D 10.2337/diabetes.51.1.168 11756337
44. H Chen M Montagnani T Funahashi, et al. 2003 Adiponectin stimulates production of nitric oxide in vascular endothelial cells J Biol Chem 278 45021 45026 1:CAS:528:DC%2BD3sXoslWlt7s%3D 10.1074/jbc.M307878200 12944390 (Pubitemid 37377262)
45. K Ohashi S Kihara N Ouchi, et al. 2006 Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47 1108 1116 1:CAS:528:DC%2BD28XksVOmu7Y%3D
46. C Giannattasio A Zoppo G Gentile, et al. 2005 Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects Arterioscler Thromb Vasc Biol 25 406 410 1:CAS:528:DC%2BD2MXmtFClsA%3D%3D 10.1161/01.ATV.0000152231.93590.17 15576637 (Pubitemid 40189165)
47. GS Hotamisligil NS Shargill BM Spiegelman 1993 Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 87 91 1:CAS:528:DyaK3sXnvFaitw%3D%3D 10.1126/science.7678183 7678183
48. T Yamauchi J Kamon H Waki, et al. 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat Med 7 941 946 1:CAS:528:DC%2BD3MXlvVOkt7o%3D 10.1038/90984 11479627 (Pubitemid 32756432)
49. VJ Stevens E Obarzanek NR Cook, et al. 2001 Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II Ann Intern Med 134 1 11 1:STN:280:DC%2BD3M%2FptFGhtg%3D%3D 11187414
50. P Ziccardi F Nappo G Giugliano, et al. 2002 Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year Circulation 105 804 809 1:CAS:528: DC%2BD38XitlOls7o%3D 10.1161/hc0702.104279 11854119 (Pubitemid 34174919)
51. AB Goldfine SE Shoelson V Aguirre 2009 Expansion and contraction: treating diabetes with bariatric surgery Nat Med 15 616 617 1:CAS:528: DC%2BD1MXmvVWnsb0%3D 10.1038/nm0609-616 19498374
52. AR Moschen C Molnar AM Wolf, et al. 2009 Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression J Hepatol 51 765 777 1:CAS:528:DC%2BD1MXhtFagt7%2FM 10.1016/j.jhep.2009.06.016 19664840
53. •• Araki K, Masaki T, Katsuragi I, et al.: Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 2008, 16:2068-2073. Pravastatin was shown to decrease diet-induced obesity, visceral WAT, adiponectin and resisitin levels, and increase oxygen consumption in animal models.
54. JK Liao 2002 Beyond lipid lowering: the role of statins in vascular protection Int J Cardiol 86 5 18 10.1016/S0167-5273(02)00195-X 12243846 (Pubitemid 35247880)
55. Y Yu K Ohmori Y Chen, et al. 2004 Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model J Am Coll Cardiol 44 904 913 1:CAS:528:DC%2BD2cXmslensr4%3D 10.1016/j.jacc.2004.04.050 15312879 (Pubitemid 39099592)
56. G Hansmann RA Wagner S Schellong, et al. 2007 Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation Circulation 115 1275 1284 1:CAS:528:DC%2BD2sXisVGjtbY%3D 17339547
57. J Mohapatra M Sharma S Singh, et al. 2009 Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice Pharmacology 84 203 210 1:CAS:528:DC%2BD1MXht1KrtLbP 10.1159/000235996 19738399
58. TP Combs JA Wagner J Berger, et al. 2002 Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization Endocrinology 143 998 1007 1:CAS:528:DC%2BD38XhvVeis7o%3D 10.1210/en.143.3.998 11861525 (Pubitemid 34164048)
59. AS Bomback PJ Klemmer 2009 Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review Am J Nephrol 30 140 146 1:CAS:528:DC%2BD1MXpvFCnt7w%3D 10.1159/000209744 19299892
60. A Whaley-Connell J Habibi Y Wei, et al. 2009 Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat Am J Physiol Renal Physiol 296 F1013 F1022 1:CAS:528: DC%2BD1MXlvFantbY%3D 10.1152/ajprenal.90646.2008 19261739
61. A Sato T Saruta JW Funder 2006 Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection Hypertens Res 29 211 216 1:CAS:528:DC%2BD28Xms1OgtLk%3D 10.1291/hypres.29.211 16778327 (Pubitemid 43853266)
62. Y Furumatsu Y Nagasawa K Tomida, et al. 2008 Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker Hypertens Res 31 59 67 1:CAS:528:DC%2BD1cXltl2ntbo%3D 10.1291/hypres.31.59 18360019 (Pubitemid 351325616)
63. Sowers J, Giles T, Ofili E, et al.: Greater efficacy with amlodipine/valsartan combination intensive vs moderate treatment for hypertensive patients with cardiometabolic syndrome uncontrolled on ARB monotherapy: Pp.34.432. J Hypertens 2010, 28:e578. doi: 10.1097/01.hjh. 0000379970.75767.bb.